Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.23
- Piotroski Score 1.00
- Grade Buy
- Symbol (LQDA)
- Company Liquidia Corporation
- Price $10.14
- Changes Percentage (0.2%)
- Change $0.02
- Day Low $9.94
- Day High $10.34
- Year High $16.99
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/11/2025
- Fiscal Year End N/A
- Average Stock Price Target $17.00
- High Stock Price Target $27.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.57
- Trailing P/E Ratio -8.77
- Forward P/E Ratio -8.77
- P/E Growth -8.77
- Net Income $-78,502,000
Income Statement
Quarterly
Annual
Latest News of LQDA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Liquidia Corp (LQDA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Regulatory ...
The earnings call discussed various topics such as the summary judgment hearing, data disclosure from the Ascent trial in 2025, potential coverage access for Yutrepia launch, and the timeline for deve...
By Yahoo! Finance | 1 week ago
